Reference
- NHLBI Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed April 20, 2010.
QVAR
® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR
® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR
® may reduce or eliminate the need for systemic corticosteroids.
QVAR
® does not replace fast-acting (rescue) inhalers for sudden symptoms.
CAUTION: If you are switching from an oral corticosteroid to QVAR®, follow your doctor's instructions to avoid health risks when you stop using oral corticosteroids (See WARNINGS, Prescribing Information).
Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult growth is unknown.
In clinical studies, common side effects included headache and pharyngitis.
Do not stop taking QVAR
® abruptly without talking to your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.
QVAR® is a registered trademark of IVAX LLC, a member of the Teva Group.
©2011 Teva Respiratory, LLC. This site is intended for U.S. residents only.
101755